What is THAR's current stock price?

THAR (Tharimmune, Inc.) is currently trading at $3.54 with a market cap of $139.9M.

What sector is Tharimmune, Inc. in?

Tharimmune, Inc. (THAR) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

THAR Tharimmune, Inc.

Healthcare

$3.54+0.00%OpenMarket Cap: $139.9M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.56

P/S

0.00

EV/EBITDA

-1.26

DCF Value

$0.50

FCF Yield

-17.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-36.9%

ROA

-13.8%

ROIC

-8.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-47.3M	$—
Q4 null	$0.00	$-29.4M	$—
FY null	$0.00	$-35.9M	$—
Q3 null	$0.00	$-2.1M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.45

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Peers

ANL

ICU